Trinity Biotech (TRIB) Current Deferred Revenue (2016 - 2020)

Trinity Biotech's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $4.4 million for Q4 2020.

• In Q4 2020, Current Deferred Revenue rose 1422.26% year-over-year to $4.4 million; the TTM figure through Dec 2020 stood at $4.4 million (up 1422.26% YoY), while the FY2020 annual figure was $4.4 million, up 1422.26% from the prior year.
• Current Deferred Revenue came in at $4.4 million for Q4 2020 at Trinity Biotech, up from $292000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $4.4 million in Q4 2020 to a low of $224000.0 in Q4 2016.
• A 5-year average of $1.1 million and a median of $292000.0 in 2019 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue slipped 6.41% in 2019 and surged 1422.26% in 2020, its largest moves.
• Trinity Biotech's Current Deferred Revenue stood at $224000.0 in 2016, then increased by 24.11% to $278000.0 in 2017, then advanced by 12.23% to $312000.0 in 2018, then retreated by 6.41% to $292000.0 in 2019, then soared by 1422.26% to $4.4 million in 2020.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.4 million, $292000.0, and $312000.0 for Q4 2020, Q4 2019, and Q4 2018 respectively.

Peer Comparison